Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 533.24 M
The data is delayed by 15 minutes.
Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements w
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||38.39 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||2.11||Price/Cash Per Share|
|Price/Free Cash Flow||-4.47||ROA||-27.31%||ROE||-76.19%||ROI|
|Current Ratio||7.93||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.22|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||1.19 M||Cash From Investing Activities||-143.03 M||Cash From Operating Activities||-48.41 M||Gross Profit|
|Net Profit||-63.14 M||Operating Profit||-64.22 M||Total Assets||704.71 M||Total Current Assets||441.7 M|
|Total Current Liabilities||55.68 M||Total Debt||287.5 M||Total Liabilities||452.12 M||Total Revenue|
|High 52 week||46.01||Low 52 week||5.68||Last close||5.68||Last change||-2.57%|
|RSI||21.21||Average true range||0.92||Beta||1.33||Volume||1.42 M|
|Simple moving average 20 days||-44.43%||Simple moving average 50 days||-54.86%||Simple moving average 200 days||-70.27%|
|Performance Week||-38.66%||Performance Month||-57.1%||Performance Quart||-70.54%||Performance Half||-77.57%|
|Performance Year||-83.79%||Performance Year-to-date||-68.37%||Volatility daily||9.98%||Volatility weekly||22.31%|
|Volatility monthly||45.72%||Volatility yearly||158.38%||Relative Volume||1318.58%||Average Volume||2.36 M|
|New High||New Low|
2019-10-09 11:22:03 | Clovis CLVS Shares Drop on Goldman Sachs' Bearish Outlook
2019-10-04 10:31:02 | J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug
2019-10-02 07:47:40 | Is Clovis Oncology, Inc.'s NASDAQ:CLVS CEO Pay Fair?
2019-09-30 09:00:01 | Implied Volatility Surging for Clovis Oncology CLVS Stock Options
2019-09-29 02:30:00 | Clovis Oncology Highlights Rubraca® rucaparib Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019
2019-09-25 11:10:03 | Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More
2019-09-24 14:08:21 | Clovis Oncology Call Volume Spikes After Downgrade
2019-09-24 11:36:03 | Clovis Gains Rights to Pre-Clinical Cancer Program for $12M
2019-09-24 08:58:00 | Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed
2019-09-04 06:00:00 | Near an All-Time Low, Is Clovis Oncology a Buy?
2019-08-31 09:32:01 | Why Is Clovis CLVS Down 36.8% Since Last Earnings Report?
2019-08-28 08:05:00 | Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference
2019-08-22 17:42:00 | Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
2019-08-19 10:15:02 | Clovis Oncology Inc CLVS President and CEO Patrick J Mahaffy Bought $279,500 of Shares
2019-08-18 10:18:44 | Who Has Been Buying Clovis Oncology, Inc. NASDAQ:CLVS Shares?
2019-08-13 10:58:59 | AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
2019-08-08 23:56:00 | 3 Stocks That Are Absurdly Cheap Right Now
2019-08-08 18:26:00 | Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes
2019-08-07 16:10:00 | Clovis Oncology to Offer $225 Million of Convertible Senior Notes
2019-08-04 17:18:24 | Edited Transcript of CLVS earnings conference call or presentation 1-Aug-19 12:30pm GMT
2019-08-02 10:04:02 | Clovis CLVS Q2 Earnings & Sales Lag Estimates, Shares Down
2019-08-02 06:24:07 | Clovis Oncology CLVS Q2 2019 Earnings Call Transcript
2019-08-01 13:11:15 | Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today
2019-07-25 10:33:02 | Will Clovis Oncology CLVS Report Negative Earnings Next Week? What You Should Know
2019-07-24 09:00:01 | What's in the Cards for Zynerba ZYNE This Earnings Season?
2019-07-16 10:51:02 | Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
2019-07-12 15:18:34 | Does Clovis Oncology, Inc. NASDAQ:CLVS Have A Particularly Volatile Share Price?
2019-07-02 08:37:12 | Do Options Traders Know Something About Clovis CLVS Stock We Don't?
2019-06-24 08:33:12 | Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
2019-06-18 08:59:12 | AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
2019-06-18 08:02:22 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.
2019-06-14 08:07:22 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.
2019-06-13 11:51:30 | Is Clovis Oncology Inc CLVS A Good Stock To Buy?
2019-06-13 08:04:52 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.
2019-06-11 08:06:00 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.
2019-06-10 08:07:14 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.
2019-06-06 16:05:00 | Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair
2019-06-06 09:31:01 | Why Is Clovis CLVS Down 25.3% Since Last Earnings Report?
2019-06-06 08:07:07 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.
2019-06-04 08:05:46 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.
2019-05-29 16:23:31 | Biotech Stocks Clobbered As Two Slammed With Sell Ratings
2019-05-29 10:08:00 | Clovis Oncology Stock Sinks on Dim View of Cancer Drug Sales